Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better

被引：0
|
作者：
Franchini, Massimo [1 ]
机构：
[1] Azienda Osped Univ Parma, Serv Immunoematol & Trasfus, Parma, Italy
来源：
BLOOD TRANSFUSION | 2010年 / 8卷 / 04期
关键词：
PREVIOUSLY UNTREATED PATIENTS; IMMUNE TOLERANCE INDUCTION; INHIBITOR DEVELOPMENT; CHILDREN; PURITY; EPIDEMIOLOGY; PRODUCTS; EFFICACY; COMPLEX; RISK;
D O I：
10.2450/2010.0067.10
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：292 / 296
页数：5
相关论文
共 50 条
  • [21] Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors
    Iorio, Alfonso
    Matino, Davide
    D'Amico, Roberto
    Makris, Michael
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (08):
  • [22] Recombinant factor VIII Fc for the treatment of haemophilia A
    Hermans, Cedric
    Mancuso, Maria Elisa
    Nolan, Beatrice
    Pasi, K. John
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (06) : 745 - 761
  • [23] RECENT ADVANCES IN THE PREPARATION OF PLASMA-DERIVED AND RECOMBINANT COAGULATION FACTOR-VIII
    BRAY, GL
    JOURNAL OF PEDIATRICS, 1990, 117 (03): : 503 - 507
  • [24] Biochemical and immunochemical investigations of different plasma-derived and recombinant factor VIII products
    Josic, D
    Stadler, M
    Buchacher, A
    Schulz, P
    Schutz, R
    Wiry, G
    Schwinn, H
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2095 - P2095
  • [25] Effect of plasma-derived or recombinant factor VIII on inhibitor development: a systematic review
    Iorio, A.
    Halimeh, S.
    Goldenberg, N.
    Kenet, G.
    Young, G.
    Brandao, L.
    HAEMOPHILIA, 2010, 16 : 74 - 74
  • [26] Interferon-gamma secretion defects in haemophilia A patients receiving highly purified plasma-derived or recombinant factor VIII
    NewtonNash, DK
    Tollerud, D
    Guevarra, L
    Gill, JC
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (03) : 554 - 560
  • [27] Recombinant Factor VIII Concentrates
    Franchini, Massimo
    Lippi, Giuseppe
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2010, 36 (05): : 493 - 497
  • [28] Viral safety of plasma-derived factor VIII and IX concentrates
    Ludlam, CA
    BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 : S19 - S23
  • [29] Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States
    Neufeld, Ellis J.
    Sidonio, Robert F., Jr.
    O'Day, Ken
    Runken, M. Chris
    Meyer, Kellie
    Spears, Jeffrey
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 762 - 769
  • [30] Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review
    Franchini, Massimo
    Tagliaferri, Annarita
    Mengoli, Carlo
    Cruciani, Mario
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 81 (01) : 82 - 93
12345